

REMARKS

Claims 1-15 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 1-12, drawn to peptides associated with Alcadein α and methods of using the peptides in diagnosis of Alzheimer's disease;

Group II, claims 1-3 and 7-12, drawn to peptides associated with Alcadein β and methods of using the peptides in diagnosis of Alzheimer's disease; and

Group III, claims 1-3 and 7-12, drawn to peptides associated with Alcadein γ and methods of using the peptides in diagnosis of Alzheimer's disease;

Group IV, claim 13, drawn to a method for screening a therapeutic agent for Alzheimer's disease by using Alcadein α ;

Group V, claim 13, drawn to a method for screening a therapeutic agent for Alzheimer's disease by using Alcadein β ;

Group VI, claim 13, drawn to a method for screening a therapeutic agent for Alzheimer's disease by using Alcadein γ ;

Group VII, claims 14-15, drawn to antibodies to Alcadein α ;

Group VIII, claims 14-15, drawn to antibodies to Alcadein β ; and

Group IX, claims 14-15, drawn to antibodies to Alcadein γ .

For the purpose of examination of the present application, Applicants elect, with traverse, Group I, Claims 1-12.

Group I is directed to peptides associated with Alcadein α and methods of using the peptides in diagnosis of Alzheimer's disease. The claims of at least Groups IV and VII should be rejoined and examined in the present application.

With regard to the invention of Group VII, Applicants respectfully note that if the protein of Group I is found to be novel and unobvious, i.e. the protein has never before been identified or isolated, antibodies against the protein, which require the protein for production, must also be novel and unobvious. As such, rejoinder of the invention of Group IV is respectfully requested.

With regard to the claim of Group IV, i.e. claim 13, this claim is directed to a method of using the peptide of elected Group I. Thus, once the invention of Group I is deemed patentable under 35 U.S.C. §§102 and 103, the invention of Group IV, is also necessarily patentable over any prior art and be rejoined.

Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures

The Examiner states that the present application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 because no sequence identification has been provided for the amino acid sequences presented in Fig. 15, 16, 18, 22 and 23 of the instant application.

The Examiner's attention is directed to Applicants' response filed on January 16, 2007 wherein the specification was amended to provide sequence identification provided for the amino acid sequences presented in Fig. 15, 16, 18, 22 and 23. Applicants have confirmed in the PAIR system that the Preliminary Amendment is of record in the application file.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, Ph.D., Registration No 40,069 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

- ☒ Attached is a Petition for Extension of Time.
- ☒ Attached hereto is the fee transmittal listing the required fees.


Application No.: 10/577,008

Docket No.: 3749-0112PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: **APR 17 2008**

Respectfully submitted,

By 
Mary Anne Armstrong, Ph.D.
Registration No.: 40,069
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant